Literature DB >> 18537724

Pharmacological strategies for neuroprotection in traumatic brain injury.

J S Jennings1, A M Gerber, M L Vallano.   

Abstract

Traumatic brain injury affects over a million Americans annually, but pharmacological therapy remains limited. Current standards of care in acute, subacute and chronic phases of injury are primarily supportive. This review discusses pharmacological strategies and future directions in patient treatment emphasizing pleiotropic agents targeting inflammation, oxidative damage, and glutamate excitotoxicity.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18537724     DOI： 10.2174/138955708784567377

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  17 in total

1.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

Review 2.  Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance.

Authors:  Merouane Bencherif
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

3.  Comparison of the effect of minocycline and simvastatin on functional recovery and gene expression in a rat traumatic brain injury model.

Authors:  Cole Vonder Haar; Gail D Anderson; Brandy E Elmore; Lynn H Moore; Amanda M Wright; Eric D Kantor; Fred M Farin; Theo K Bammler; James W MacDonald; Michael R Hoane
Journal:  J Neurotrauma       Date:  2014-01-20       Impact factor: 5.269

4.  Enriched Endogenous Omega-3 Fatty Acids in Mice Ameliorate Parenchymal Cell Death After Traumatic Brain Injury.

Authors:  Huixia Ren; Zhen Yang; Chuanming Luo; Haitao Zeng; Peng Li; Jing X Kang; Jian-Bo Wan; Chengwei He; Huanxing Su
Journal:  Mol Neurobiol       Date:  2016-05-11       Impact factor: 5.590

5.  A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery following Traumatic Brain Injury.

Authors:  Todd C Peterson; Michael R Hoane; Keith S McConomy; Fred M Farin; Theo K Bammler; James W MacDonald; Eric D Kantor; Gail D Anderson
Journal:  J Neurotrauma       Date:  2015-02-26       Impact factor: 5.269

6.  Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model.

Authors:  Gail D Anderson; Todd C Peterson; Cole Vonder Haar; Fred M Farin; Theo K Bammler; James W MacDonald; Eric D Kantor; Michael R Hoane
Journal:  AAPS J       Date:  2015-06-12       Impact factor: 4.009

7.  Acute NMDA toxicity in cultured rat cerebellar granule neurons is accompanied by autophagy induction and late onset autophagic cell death phenotype.

Authors:  Shankar Sadasivan; Zhiqun Zhang; Stephen F Larner; Ming C Liu; Wenrong Zheng; Firas H Kobeissy; Ronald L Hayes; Kevin K W Wang
Journal:  BMC Neurosci       Date:  2010-02-18       Impact factor: 3.288

8.  Histone deactylase inhibition combined with behavioral therapy enhances learning and memory following traumatic brain injury.

Authors:  P K Dash; S A Orsi; A N Moore
Journal:  Neuroscience       Date:  2009-06-13       Impact factor: 3.590

9.  PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms.

Authors:  Jae-Hyuk Yi; Seung-Won Park; Nathaniel Brooks; Bradley T Lang; Raghu Vemuganti
Journal:  Brain Res       Date:  2008-10-09       Impact factor: 3.252

Review 10.  Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis.

Authors:  James W Bales; Amy K Wagner; Anthony E Kline; C Edward Dixon
Journal:  Neurosci Biobehav Rev       Date:  2009-04-01       Impact factor: 8.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.